Table 6.
Effect of Saroglitazar in Swiss albino mice.
| Group | Triglycerides (mg/dL) | IVLTT-AUCtriglyceride (mg/dL · min) |
|---|---|---|
| Control | 100.3 ± 8.5 | 5918.0 ± 316.0 |
| Saroglitazar (0.01 mg/kg) | 69.6 ± 7.2* | 4654.0 ± 796.0 |
| Saroglitazar (0.03 mg/kg) | 73.8 ± 7.5* | 4447.0 ± 545.0 |
| Saroglitazar (0.1 mg/kg) | 45.9 ± 3.2* | 3739.0 ± 519* |
| Saroglitazar (0.3 mg/kg) | 59.5 ± 5.1* | 3739.0 ± 519* |
| Saroglitazar (1 mg/kg) | 36.6 ± 3.2* | 2722.0 ± 141* |
| Saroglitazar (3 mg/kg) | 31.8 ± 3.8* | 2379.0 ± 98* |
| Saroglitazar (10 mg/kg) | 24.1 ± 2.3* | 1909.0 ± 315* |
All values are measured at the end of treatment (6th day) serum TG, and IVLTT-AUC measured on day-7, values expressed as mean ± SEM. (n = 6).
ED50Values: TG reduction – 0.09 mg/kg.
*
P < 0.05 as compared to control (ANOVA).